Parsa, Shyon
Jain, Sneha S.
Akinrimisi, Olu
Lam, Carolyn S. P.
Mahaffey, Kenneth W.
Article History
Received: 26 May 2024
Accepted: 23 July 2024
First Online: 17 August 2024
Declarations
:
: Sneha S. Jain reports consulting fees from Bristol Myers Squibb, ARTIS Ventures, and Broadview Ventures outside of the submitted work. Carolyn S. P. Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Novo Nordisk and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Alleviant Medical, Allysta Pharma, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Biopeutics, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, CardioRenal, CPC Clinical Research, Eli Lilly, Hanmi, Impulse Dynamics, Intellia Therapeutics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Quidel Corporation, Radcliffe Group Ltd., Recardio Inc, ReCor Medical, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics, and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. Kenneth W. Mahaffey is supported by the American Heart Association, Apple Inc., Bayer Pharmaceuticals, the California Institute for Regenerative Medicine, Commonwealth Serum Laboratories (CSL), Eldos, Gilead, Idorsia, Johnson & Johnson (J&J), Luitpold, Novartis, the PAC-12, Precondior, Sanifit, and Verily (Google). He reports consulting fees from Applied Therapeutics, Bayer, Bristol Meyer Squibb, BridgeBio, CSL Behring, Elsevier, Fuson, Human, J&J, Moderna, Myokardia, Novartis, Novo Nordisk, Otsuka, Phasebio, Portola, Quidel, and Theravance. He reports equity holdings in Human, Medeloop, Precordior, and Regencor. Kenneth W. Mahaffey is an editorial board member of Cardiology and Therapy. Kenneth W. Mahaffey was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Shyon Parsa has nothing to disclose. Olu Akinrimsi has nothing to disclose.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.